Cannabis based products for medicinal use in humans (CBPMs)
An assessment of the impact of rescheduling CBPMs to Schedule 2 under the Misuse of Drugs Regulations 2001 (MDR) and recommendations to mitigate the issues identified.
Documents
Details
In June 2018, the then Home Secretary announced the government’s intention to commission a two-part review of cannabis and cannabis related products.
The findings of the first review provided by Professor Dame Sally Davies, recommended that cannabis based medicinal products are moved out of Schedule 1 of the Misuse of Drugs Regulations 2001 (MDR). The ACMD were then formally commissioned in July 2018 to consider the appropriate scheduling of cannabis and cannabis related products under the MDR and whether there are further provisions that could be made to reduce the risks of harm and diversion.
Utilising the ACMD’s 2019 impact assessment framework, the ACMD the compiled data to populate the framework (using information currently available) with the targeted datasets.
To examine change over time, where possible, datasets representing three time periods were examined, one before and two after the change in scheduling.
This report will attempt to assess these data to quantify the factors listed in the impact assessment framework – and to ultimately draw conclusions regarding the impact of the rescheduling of CBPMs to Schedule 2 of the MDR.